Interestingly, recent clinical trials have demonstrated that trastuzumab deruxtecan (T-DXd) is effective in patients with HER2-low metastatic BC [13], with modest anti-tumor activity also observed in HER2 ultra-low or even zero patients [14]. The gene discussed is ERBB2; the disease is neoplasm.